<DOC>
	<DOCNO>NCT02068521</DOCNO>
	<brief_summary>Protocol 13VR3 multi-center , open-label study assess long-term somavaratan administration . Patients monitor safety throughout participation study . Safety monitor physical examination , inspection injection site , vital sign , clinical laboratory determination ( include fast glucose , insulin , lipid ) , 12-lead ECGs ( new treatment naïve subject subject previously expose somavaratan ) , PK/PD assessment , immunogenicity assessment . Adverse event ( AEs ) concomitant medication capture . AEs cod use CTCAE v 4.0. AEs cod use MedDRA dictionary CMs use WHO Drug dictionary .</brief_summary>
	<brief_title>Versartis Long-Term Safety Study Somavaratan</brief_title>
	<detailed_description>Protocol 13VR3 multi-center , open-label study assess long-term somavaratan administration . It open subject complete somavaratan study child growth hormone deficiency ( GHD ) , well 100 new treatment naïve subject GHD . All subject receive somavaratan 3.5 mg/kg twice monthly . The study conduct approximately 70 Pediatric Endocrinology center United States , Canada , Europe .</detailed_description>
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Inclusion Criteria Subjects Completing Previous Somavaratan Study : 1 . Completion somavaratan clinical study . 2 . Willing able comply study procedure . Exclusion Criteria Subjects Completing Previous somavaratan Study : 1 . Withdrawal somavaratan clinical study . 2 . Use certain medication potential alter response test product . 3 . Presence significant medical condition . Inclusion Criteria New Treatment Naïve Subjects : 1 . Chronological Age ≥ 3.0 year . 2 . Prepubertal status . 3 . Diagnosis GHD document two GH stimulation test result ≤ 10.0 ng/mL . 4 . Normal thyroid function Screening Visit subject treat hypothyroidism . 5 . Normal adrenal function Screening Visit within 6 month Screening Visit , subject treated adrenal insufficiency . Subjects adrenal insufficiency must receive glucocorticoid treatment minimum 4 week study drug administration . 6 . Pathology relate cause GHD must stable least 6 month prior screen . 7 . Legally authorized representative must willing able give inform consent . Exclusion Criteria New Treatment Naïve Subjects : 1 . Prior/concomitant treatment growth promote agent . 2 . Current , significant disease . 3 . Chromosomal aneuploidy , significant gene mutation confirm diagnosis name syndrome . 4 . Birth weight and/or birth length le 5th percentile gestational age . 5 . Prolonged daily use antiinflammatory dos oral glucocorticoid . 6 . Prior history malignancy . 7 . Treatment investigational drug 30 day prior screen . 8 . Known allergy constituent study drug formulation . 9 . Ocular finding suggestive increase intracranial pressure and/or retinopathy screening . 10 . Significant spinal abnormality include scoliosis , kyphosis , Chiari malformation , spina bifida variant . 11 . Significant abnormality screen study . 12 . History pancreatitis undiagnosed chronic abdominal pain . 13 . History spinal total body irradiation . 14 . Other pituitary hormone deficiency properly treat .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Growth Hormone Deficiency</keyword>
	<keyword>Pediatric Growth Hormone Deficiency</keyword>
	<keyword>GHD</keyword>
	<keyword>PGHD</keyword>
	<keyword>VRS-317</keyword>
	<keyword>Versartis</keyword>
	<keyword>Growth disorder</keyword>
	<keyword>Long act growth hormone</keyword>
	<keyword>Growth hormone</keyword>
	<keyword>Weekly growth hormone dosing</keyword>
	<keyword>Semi-monthly growth hormone dosing</keyword>
	<keyword>Monthly growth hormone dosing</keyword>
	<keyword>IGF-I</keyword>
	<keyword>Short stature</keyword>
	<keyword>Height velocity</keyword>
	<keyword>Annual height velocity</keyword>
	<keyword>Growth rate</keyword>
	<keyword>Somavaratan</keyword>
</DOC>